| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 27, 2024 |
| Accession Number: | 0001104659-24-027601 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/27/2023 | Outperform | Evercore ISI | |
| 10/19/2023 | $11.00 | Buy | Stifel |
| 3/27/2023 | $7.00 | Overweight | Wells Fargo |
| 12/8/2022 | $6.00 | Buy | H.C. Wainwright |
| 9/22/2022 | $12.00 | Buy | Citigroup |
| 8/18/2022 | Overweight | Wells Fargo | |
| 6/1/2022 | $20.00 | Overweight | Cantor Fitzgerald |
| 4/4/2022 | $18.00 | Buy | BTIG Research |
Stifel analyst Benjamin Burnett downgrades Gracell Biotechnologies (NASDAQ:GRCL) from Buy to Hold and lowers the price target from $11 to $10.25.
Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that at an extraordinary general meeting of shareholders (the "EGM") held on February 19, 2024, the Company's shareholders voted in favor of the proposal to approve and authorize the execution, delivery and performance by the Company of the previously announced Agreement and Plan of Merger, dated as of December 23, 2023 (the "Merger Agreement"), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorp
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease, today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the "Merger Agreement"), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales ("Parent"), and Grey Wolf Merger Su
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that at an extraordinary general meeting of shareholders (the "EGM") held on February 19, 2024, the Company's shareholders voted in favor of the proposal to approve and authorize the execution, delivery and performance by the Company of the previously announced Agreement and Plan of Merger, dated as of December 23, 2023 (the "Merger Agreement"), by
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared Gracell's Investigational New Drug (IND) application, allowing the Company to initiate a Phase 1 clinical trial of GC012F in the United States for the early-line treatment of multiple myeloma (ELMM). "We are extremely pleased to receive our third U.S. IND clearance for our lead FasTCAR ca
Evercore ISI initiated coverage of Gracell Biotechnologies with a rating of Outperform
Stifel initiated coverage of Gracell Biotechnologies with a rating of Buy and set a new price target of $11.00
Wells Fargo resumed coverage of Gracell Biotechnologies with a rating of Overweight and set a new price target of $7.00
15-12G - Gracell Biotechnologies Inc. (0001826492) (Filer)
EFFECT - Gracell Biotechnologies Inc. (0001826492) (Filer)
EFFECT - Gracell Biotechnologies Inc. (0001826492) (Filer)
SC 13G/A - Gracell Biotechnologies Inc. (0001826492) (Subject)
SC 13G/A - Gracell Biotechnologies Inc. (0001826492) (Subject)
SC 13G - Gracell Biotechnologies Inc. (0001826492) (Subject)
Dr. Li brings deep oncology clinical development, medical affairs and U.S. regulatory experience SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Aug. 1, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Wendy Li, M.D., as its Chief Medical Officer (CMO). In this role, Dr. Li will oversee Gracell's clinical development activities, including the advancement of its pipeline of autologous and allogeneic product candidates across the Company's multiple proprie
SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, July 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced the appointment of Samuel Zhang, Ph.D., as its Chief Business Officer (CBO). In this role, Dr. Zhang will be responsible for strategic leadership of Gracell's global business development and corporate strategy, including structuring, negotiating and executing of strategic alliances and collaborations.
Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) Expect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the fourth quarter 2023Presented longer-term follow-up data from an ongoing Phase 1 investigator-initiated trial (IIT) evaluating GC012F as a frontline treatment for patients with transplant-eligible, high-risk, newly diagnosed multiple myeloma (NDMM); updated data to be reported as an oral presentation at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition (ASH 2023)On track to submit IND filings for planned Phase 1 clinical tr
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2023 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 13, 2023. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time. Conference call and webcast details:Monday, Nov
Commenced Phase 1b/2 clinical trial in U.S. evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) and patient screening underway in Phase 1b portionExpect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the third quarter of 2023On track to submit US IND filing for planned Phase 1 trial of GC012F in refractory systemic lupus erythematosus (rSLE) in 2023Dosed multiple patients in the investigator-initiated trial (IIT) in China evaluating GC012F in rSLEClosed a private placement of ordinary shares and warrants to generate $100 million upfront and up to $50 million tied to exercise of warrants, extending cash run